Skip to content

Nutritional Supplements: Understanding the Responses in Strength and Endurance Training

Nutritional supplements and responses to different physical activity programs

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-10vqn68h
Enrollment
Unknown
Registered
2025-10-31
Start date
2025-11-10
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physical Performance

Interventions

This is a randomized, controlled, double-blind, two-arm clinical trial. The Caffeine Group (CA) will consist of 10 healthy men who will receive, 60 minutes before the assessments, a dose of 0.6 g/kg o

Sponsors

Universidade Federal de Lavras
Lead Sponsor
Universidade Federal de Lavras
Collaborator

Eligibility

Sex/Gender
Male
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Male individuals who regularly practice physical activity; Age between 18 and 35 years; Regular practice of physical activity for at least 24 months

Exclusion criteria

Exclusion criteria: Smoker; Patients with diabetes and/or cardiovascular diseases; History of osteoarticular injury in the last six months. Use of any ergogenic resource and / or dietary supplement; Failure to attend LEMOH or the Sports Nutrition Laboratory on the days of tests

Design outcomes

Primary

MeasureTime frame
The acute ingestion of 210 mg of caffeine proved to be effective in improving the performance of The acute ingestion of 210 mg of caffeine will be effective in improving the performance of CrossFit® practitioners when performing a benchmark of the modality, reducing completion time and lower limb power.

Secondary

MeasureTime frame
Acute caffeine supplementation will bring benefits to the subjective perception of exertion (RPE), delayed onset muscle soreness (DOMS) and muscle thickness.

Countries

Brazil

Contacts

Public ContactSandro da Silva

Universidade Federal de Lavras

sandrofs@ufla.br+553538295132

Outcome results

None listed

Source: REBEC (via WHO ICTRP)